Voyager Therapeutics, Inc. (BMV:VYGR)

Voyager Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-107.93	-65	132.33	-46.41	-71.2	36.74
Depreciation & Amortization	4.22	4.73	4.44	6.19	5.17	3.82
Stock-Based Compensation	14.98	14.79	11.15	9.34	11.32	14.93
Other Adjustments	-5.06	-4.68	-3.45	-2.11	-2.11	-7.67
Change in Receivables	0.73	81.31	-83.23	0.48	7.28	10.48
Changes in Accounts Payable	-0.8	2.39	-0.96	1.99	-0.06	-3.44
Changes in Accrued Expenses	1.75	-2.65	9.01	-3.15	-3.34	-6.48
Changes in Unearned Revenue	-16.86	-44.84	9.41	23.73	-1.72	-150.68
Changes in Other Operating Activities	-9.21	-1.35	-0.78	-2.58	1.13	5.57
Operating Cash Flow	-113.65	-15.31	77.92	-12.51	-53.53	-96.72
Capital Expenditures	-2.18	-3.52	-3.26	-2.49	-1.61	-12.1
Purchases of Investments	-286.62	-465.69	-223.97	-54.85	-15.12	-70.4
Proceeds from Sale of Investments	369.08	374.35	85.58	50	82.63	195.5
Investing Cash Flow	80.28	-94.86	-141.64	-7.34	65.91	113
Issuance of Common Stock	0.38	114.02	33.65	1.11	0.61	3.16
Net Common Stock Issued (Repurchased)	0.38	114.02	33.65	1.11	0.61	3.16
Financing Cash Flow	1.18	114.02	33.65	1.11	0.61	3.16
Net Cash Flow	-32.19	3.85	-30.08	-18.74	12.99	19.44
Beginning Cash & Cash Equivalents	79	70.4	100.47	119.21	106.22	86.78
Ending Cash & Cash Equivalents	46.81	74.24	70.4	100.47	119.21	106.22
Free Cash Flow	-115.83	-18.83	74.66	-15	-55.13	-108.81
FCF Margin	-272.03%	-23.54%	29.86%	-36.67%	-147.36%	-63.59%
Free Cash Flow Per Share	-1.99	-0.33	1.68	-0.39	-1.46	-2.91
Levered Free Cash Flow	-131.01	-110.24	150.19	-22.71	-71.63	-126.56
Unlevered Free Cash Flow	-147.26	-129.39	138.59	-27.16	-74.05	-135.92

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.